Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Phase II data on potential new therapy for the treatment of breast cancer announced
January 12th, 2006
Researchers presented preliminary safety and efficacy data for E7389 in the treatment of advanced, refractory breast cancer during the San Antonio (Texas) Breast Cancer Symposium. E7389 is a synthetic analog of halichondrin B, which is a natural product shown in preclinical studies to have highly potent anticancer activity in vitro and in vivo. Halichondrin B was originally isolated from a type of marine sponge. This study was designed to evaluate E7389 as a monotherapy in patients with refractory breast cancer. The primary endpoint of this trial was response rate, measured using the response evaluation criteria in solid tumors...
Source: Women's Health Weekly (2006-01-12)
|
